Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1472

Similar articles for PubMed (Select 8443901)

1.
2.

Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.

Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ.

J Am Coll Cardiol. 1999 May;33(6):1596-601.

3.

Implantable cardioverter defibrillator therapy for life-threatening arrhythmias in young patients.

Stefanelli CB, Bradley DJ, Leroy S, Dick M 2nd, Serwer GA, Fischbach PS.

J Interv Card Electrophysiol. 2002 Jul;6(3):235-44.

PMID:
12154326
4.

Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors.

Wever EF, Hauer RN, van Capelle FL, Tijssen JG, Crijns HJ, Algra A, Wiesfeld AC, Bakker PF, Robles de Medina EO.

Circulation. 1995 Apr 15;91(8):2195-203.

5.

[14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].

Vester EG, Dees H, Dobran I, Hennersdorf M, Perings C, Heydthausen M, Winter J, Strauer BE.

Z Kardiol. 2000;89 Suppl 3:194-205. German.

PMID:
10810803
6.

Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.

Hilleman DE, Bauman AL.

Pharmacotherapy. 2001 May;21(5):556-75. Review.

PMID:
11349745
7.

Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2005;5(14):1-74. Epub 2005 Sep 1.

8.

[Implantable cardioverter-defibrillators in patients resuscitated from sudden death and in patients with sustained refractory ventricular tachycardia].

Adragão P, Parreira L, Neves J, Morgado F, Abecassis M, Almeida M, Martins D, Bonhorst D, Seabra-Gomes R.

Rev Port Cardiol. 1996 Mar;15(3):195-206, 179, 181. Portuguese.

PMID:
8634168
9.

Implantable cardioverter-defibrillator therapy in survivors of out-of-hospital sudden cardiac death without inducible arrhythmias.

Crandall BG, Morris CD, Cutler JE, Kudenchuk PJ, Peterson JL, Liem LB, Broudy DR, Greene HL, Halperin BD, McAnulty JH, et al.

J Am Coll Cardiol. 1993 Apr;21(5):1186-92.

PMID:
8459075
10.

Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L.

Pacing Clin Electrophysiol. 2003 Sep;26(9):1887-96.

PMID:
12930505
11.

Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia.

Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, Salerno JU, Igidbashian D, Raviele A, Disertori M, Zanotto G, Verlato R, Vergara G, Delise P, Turrini P, Basso C, Naccarella F, Maddalena F, Estes NA 3rd, Buja G, Thiene G.

Circulation. 2003 Dec 23;108(25):3084-91. Epub 2003 Nov 24.

12.
13.

New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.

Klein H, Auricchio A, Reek S, Geller C.

Am J Cardiol. 1999 Mar 11;83(5B):91D-97D. Review.

PMID:
10089848
14.

[The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].

Marín F, Gimeno JR, Payá E, García-Alberola A, Pérez-Alvarez L, Fernández X, de la Morena G, Sogorb F, Castro-Beiras A, Valdés M, Martínez JG, Monserrat L.

Rev Esp Cardiol. 2006 Jun;59(6):537-44. Spanish.

15.

A Latin American registry of implantable cardioverter defibrillators: the ICD-LABOR study.

Dubner S, Valero E, Pesce R, Zuelgaray JG, Mateos JC, Filho SG, Reyes W, Garillo R.

Ann Noninvasive Electrocardiol. 2005 Oct;10(4):420-8.

PMID:
16255752
16.

[Short-term and long-term outcome of left heart function after cardioverter defibrillator implantation].

Takeichi K, Kasanuki H, Ohnishi S, Endoh Y, Hosoda S.

J Cardiol. 1996 Nov;28(5):277-86. Japanese.

PMID:
8953401
17.

Hypertrophic cardiomyopathy: the importance of arrhythmic events in patients at risk for sudden cardiac death.

Medeiros Pde T, Martinelli Filho M, Arteaga E, Costa R, Siqueira S, Mady C, Piegas LS, Ramires JA.

Arq Bras Cardiol. 2006 Nov;87(5):649-57. English, Portuguese.

18.

A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.

Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. Review.

19.

Shock occurrence and survival in 241 patients with implantable cardioverter-defibrillator therapy.

Grimm W, Flores BT, Marchlinski FE.

Circulation. 1993 Jun;87(6):1880-8.

PMID:
8504500
20.

Long-term incidence of malignant ventricular arrhythmia and shock therapy in patients with primary defibrillator implantation does not differ from event rates in patients treated for survived cardiac arrest.

Backenköhler U, Erdogan A, Steen-Mueller MK, Kuhlmann C, Most A, Schaefer C, Stertmann W, Waas W, Tillmanns H, Waldecker B.

J Cardiovasc Electrophysiol. 2005 May;16(5):478-82.

PMID:
15877617
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk